Calendar

Cloudflare’s reported Q2 2026 revenue growth and a $736.8M Q3 revenue consensus provide a credible business backdrop, but the stock fell sharply into the event: it lost roughly 15.5% from Oct. 26 to Oct. 30, including a high-volume down day. Required positive tape and estimate-upside signals are not supported.

ABNB has a small positive whisper-versus-consensus gap and recent company guidance describes strong revenue growth, but the guidance midpoint is slightly below the checked revenue consensus. The stock fell about 4.4% over five sessions, had no close above the 0.75 close-location threshold in the latest three sessions, and no confirmed 1.5x volume session; it does not qualify despite a supportive XLY tape.

EOG has upward EPS estimate revisions, a credible Q3 consensus, and a strong Oct. 30 close, but available checks did not establish positive revenue revisions or a recent >1.5x-volume accumulation day. The company has scheduled its Q3 results for Nov. 5 after close; its IR page separately lists a Nov. 6 results call.

Lumentum's September-quarter EPS estimate rose from $4.21 to $4.22 over the last month, and its prior company guidance midpoint for $1.25B revenue is in line with reported consensus; management cited accelerating AI-driven optical demand and the stock advanced sharply over the preceding five sessions. However, the late-week reversal and lack of a verified normal-volume comparator temper the setup, while valuation and execution risks remain material.

Simon has positive, though non-uniform, estimate momentum: checked consensus showed EPS up 1.74% and revenue up 3.69% over three months, and its latest reported quarter showed 96.0% occupancy, higher retailer sales, and raised full-year FFO guidance. The stock gained about 2.4% over five sessions and closed near the top of its Oct 30 range, but a normal-volume comparison was unavailable and its recent earnings history is uneven.

DVN has positive near-term estimate revisions, rising revenue expectations, four recent EPS beats per Zacks, and an official Nov. 5 reporting date; the stock also strengthened into the event. However, earnings-whisper EPS is below some consensus figures and the shares lagged the energy sector over the past month, while commodity exposure and transaction execution leave meaningful uncertainty.

Earnings Whispers reports a $1.48 whisper against $1.39 consensus, while the prior quarter had strong reported growth; however, no reliable pre-event revenue-revision, verified close-location, or volume-accumulation evidence was found for this screen, and the supplied latest close does not establish recent strength. The positive whisper alone is insufficient for qualification.

ED's reported date and consensus figures were available, and the recent close rose with XLU supportive; Con Edison had reaffirmed its 2026 adjusted EPS guidance. But no positive EPS revision, ESP, whisper, or revenue-upside signal was verified, and none of the last three checked sessions closed in the upper quarter of its range.

A pre-event Zacks article says the estimate-revision combination points toward a likely EPS beat, and recent annualized recovery expectations offer a possible cyclical catalyst. However, exact revision and current-quarter revenue consensus/upside evidence was not verifiable in the checked results, while Oct. 30 brought a high-volume 4.66% selloff and a weak close; it fails the required tape confirmation.

Live Nation has strong operating indicators ahead of the report: the latest available filing said 2026 event ticket sales were pacing 11% higher and deferred revenue reached a second-quarter record, while the stock recovered into Oct. 30 on a large-volume up day. But current-quarter revenue consensus estimates varied across checked providers and no positive EPS revision/ESP/whisper was verified; score remains below the required threshold.

The supplied Nov. 5 date conflicts with checked earnings sources: Earnings Whispers and MarketBeat indicate Nov. 4, while another estimate page shows Nov. 5 and cautions the date may move. Consensus estimates exist, but no positive revisions or required tape confirmation were established; reject on unconfirmed event date and incomplete signals.

MRNA has a modestly favorable EPS revision snapshot and a recent high-volume rebound, but the checked calendar sources describe Nov. 6 as estimated rather than company-confirmed, and no positive revenue revision or upside indicator was verified. The Oct. 22 melanoma-trial data leak coincided with a 17.57% drop and unusually high volume, leaving a volatile, event-driven tape.

Record Q2 fundraising and 20% fee-related-earnings growth, alongside a rising recent share price and several analyst target cuts, create a constructive but mixed backdrop. The checked sources support EPS and revenue consensus, but do not establish positive estimate revisions or an upside surprise signal; recent volume also falls short of a verified accumulation trigger.

Humana's primary IR estimate table showed near-flat Q3 EPS revisions and a credible consensus source provides EPS and revenue estimates, but the stock weakened into the event and underperformed the rising XLV. Medical-cost and Medicare policy uncertainty remain material, while recent tape did not confirm accumulation.

Vistra has a company-confirmed Nov. 6 report date and a strongly positive 30-day Q3 EPS revision, alongside long-term power-demand catalysts. However, shares declined about 5.4% from Oct. 26 through Oct. 30, recent closes were weak in their daily ranges, and the latest quarter missed consensus materially. Positive revisions alone do not offset the poor pre-event tape and limited recent execution evidence.

The reported initial after-hours decline of about 4.5% reversed in regular trading: STZ rose 2.35% on October 7 and 4.43% on October 8, closing at the $123.63 anchor. Those two closes put the stock about 6.9% above its October 6 close, but do not prove stronger underlying beer demand. Post-print news and analyst views are mixed: Goldman Sachs and BofA cut targets, while BMO reportedly reiterated its target. Broader forward-estimate revisions, reliable social coverage, options skew and short-interest readings remain unavailable. [After-hours report](https://www.tipranks.com/news/why-did-constellation-brands-stock-fall-over-4-in-after-hours-trading-on-october-6) [Historical prices](https://stockanalysis.com/stocks/stz/history/) [Goldman Sachs reaction](https://www.investing.com/news/analyst-ratings/goldman-sachs-lowers-constellation-brands-stock-price-target-on-weaker-secondhalf-outlook-93CH-4937291) [BofA reaction](https://www.tipranks.com/news/the-fly/constellation-brands-price-target-lowered-to-120-from-145-at-bofa-thefly-news) [BMO report](https://www.tikr.com/blog/constellation-brands-has-lost-29-since-february-bmo-sees-60-upside)

The October 6 close of $98.31 was 3.16% above the October 5 pre-release close of $95.30. Shares then closed at $98.33 on October 7 and $99.43 on October 8: the initial gain held, but the October 8 close was only about 0.2% above October 2, before the sharp October 5 decline. Multiple post-print target cuts temper the favorable immediate reaction. No verified post-print EPS-estimate revisions or analyst rationales were available. No reliable social, options, short-interest or employee-sentiment readings were supplied; zeros in those fields denote unavailable data, not measured neutrality. [Historical prices](https://stockanalysis.com/stocks/rpm/history/) [October 7 analyst updates](https://www.stocktargetadvisor.com/blog/u-s-analyst-updates-october-7th-2026/) [October 8 Deutsche Bank update](https://www.gurufocus.com/news/9115870/rpm-maintained-by-deutsche-bank-price-target-lowered-to-115)

The print and raised guidance improved the near-term news tone. Adjusted EPS of $0.75 exceeded a reported $0.59 estimate, while sales exceeded consensus by about 1%; consensus figures are from [Zacks coverage](https://finance.yahoo.com/markets/stocks/articles/lamb-weston-lw-surpasses-q1-121002996.html), not the company release. LW [closed up 7.49% on October 6](https://stockanalysis.com/stocks/lw/history/) and the packet anchors it at $49.46 on October 8, so part of the improvement is reflected in price. Selected analyst targets rose, but broad estimate-revision data are unavailable. Social coverage, options skew, short interest and employee score were not established; zeros in those fields mean unavailable, not neutral readings. The deterministic prior remains neutral despite a meaningful earnings update.

News tone is positive but analyst interpretation remains split. Reported Q4 EPS of $1.00 exceeded a $0.77 consensus, and sales of $567 million exceeded roughly $521 million; shares closed October 7 at $72.61, up 13.1% from October 6, then eased to the $71.57 October 8 anchor. Several targets rose after the print, while Barclays remained Underweight. [Consensus and revisions](https://stockanalysis.com/stocks/peng/) [Price history](https://fundlibrary.com/Stocks/Detail/447467?FundName=Penguin+Solutions+Inc.) Social, options-skew, short-interest and employee-review measures are unavailable; their zero fields are placeholders, not observed readings.

Earnings coverage is favorable on the EPS beat and raised profit and cash-flow outlook, but the October 8 close of $26.55 was only 3.91% above October 7's $25.55 after opening at $31.33—a substantial intraday fade. [Price history](https://stockanalysis.com/stocks/hele/history/) No verified post-print analyst revisions are available. The positive structured prior supports upgrading the prior negative thesis to cautiously constructive monitoring, not a high-conviction buy. Zero social, options, short-interest and employee fields indicate unavailable measures, not neutral readings.

The October 1 close fell 4.87% after the earnings release despite the reported revenue and adjusted-EPS beats. Shares subsequently recovered from $44.14 to the packet's $45.25 October 7 anchor but remained below the September 30 close of $46.40; the price record does not establish the cause of the decline. Five reported October 2 target cuts temper the positive deterministic prior, and verified post-print EPS-estimate revisions are unavailable. News tone is mixed. The zero social, options, short-interest and employee entries represent unavailable inputs, not measured neutrality. The scheduled follow-up cites an October 5 earnings date, but the company release and SEC 8-K establish that Q3 results were announced October 1. [Price history](https://stockanalysis.com/stocks/mkc/history/) [Benzinga analyst actions](https://www.benzinga.com/quote/MKC/price-targets) [#SEC-8K-2026-10-01] [SEC filing](https://www.sec.gov/Archives/edgar/data/63754/000006375426000326/mkc-20261001.htm)

Addus HomeCare Announces First Quarter 2026 Financial Results